Condition: Schizophrenia · Bipolar I Disorder · Sponsor: Vanda Pharmaceuticals
To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.
This description comes directly from the study's public registry record.
Vanda Pharmaceuticals Inc. · 202-734-3400 · clinicaltrials@vandapharma.com
Always discuss trial participation with your own doctor first.
| Vanda Investigational Site | Little Rock, Arkansas, United States | Recruiting |
| Vanda Investigational Site | Denver, Colorado, United States | Recruiting |
| Vanda Investigational Site | Atlanta, Georgia, United States | Recruiting |
| Vanda Investigational Site | Atlanta, Georgia, United States | Recruiting |
| Vanda Investigational Site | Decatur, Georgia, United States | Recruiting |
| Vanda Investigational Site | Cincinnati, Ohio, United States | Recruiting |
| Vanda Investigational Site | Garfield Heights, Ohio, United States | Recruiting |
| Vanda Investigational Site | Westlake, Ohio, United States | Not Yet Recruiting |
| Vanda Investigational Site | Everett, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05648591